Abstract:Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, and prognosis assessment is crucial for guiding treatment decisions. In this study, we aimed to develop a personalized prognostic model for HCC based on RNA editing. RNA editing is a post-transcriptional process that can affect gene expression and, in some cases, play a role in cancer development. By analyzing RNA editing sites in HCC, we sought to identify a set of sites associated with patient prognosis and use them to create a prognostic model. We gathered RNA editing data from the Synapse database, comprising 9990 RNA editing sites and 250 HCC samples. Additionally, we collected clinical data for 377 HCC patients from the Cancer Genome Atlas (TCGA) database. We employed a multi-step approach to identify prognosis-related RNA editing sites (PR-RNA-ESs). We assessed how patients in the high-risk and low-risk groups, as defined by the model, fared in terms of survival. A nomogram was developed to predict the precise survival prognosis of HCC patients and assessed the prognostic model's utility through a receiver operating characteristic (ROC) analysis and decision curve analysis (DCA). Our analysis identified 33 prognosis-related RNA editing sites (PR-RNA-ESs) associated with HCC patient prognosis. Using a combination of LASSO regression and cross-validation, we constructed a prognostic model based on 13 PR-RNA-ESs. Survival analysis demonstrated significant differences in the survival outcomes of patients in the high-risk and low-risk groups defined by this model. Additionally, the differential expression of the 13 PR-RNA-ESs played a role in shaping patient survival. Risk-prognostic investigations further distinguished patients based on their risk levels. The nomogram enabled precise survival prognosis prediction. Our study has successfully developed a highly personalized and accurate prognostic model for individuals with HCC, leveraging RNA editing data. This model has the potential to revolutionize clinical evaluation and medical management by providing individualized prognostic information. The identification of specific RNA editing sites associated with HCC prognosis and their incorporation into a predictive model holds promise for improving the precision of treatment strategies and ultimately enhancing patient outcomes in HCC.

A-to-I RNA co-editing predicts clinical outcomes and is associated with immune cells infiltration in hepatocellular carcinoma

Genomic Identification of RNA Editing Through Integrating Omics Datasets and the Clinical Relevance in Hepatocellular Carcinoma

Genome-wide Identification of RNA Editing in Hepatocellular Carcinoma.

Transcriptome Sequencing of Hepatocellular Carcinoma Uncovers Multiple Types of Dysregulated Ncrnas

A Disrupted RNA Editing Balance Mediated by ADARs (adenosine DeAminases That Act on RNA) in Human Hepatocellular Carcinoma

Prognostic analysis and risk assessment based on RNA editing in hepatocellular carcinoma

CDK13 RNA Over-Editing Mediated by ADAR1 Associates with Poor Prognosis of Hepatocellular Carcinoma Patients.

Liver cancer-specific mutations in functional domains of ADAR2 lead to the elevation of coding and non-coding RNA editing in multiple tumor-related genes

A-to-I nonsynonymous RNA editing was significantly enriched in the ubiquitination site and correlated with clinical features and immune response

Identification of A-to-I RNA Editing Profiles and Their Clinical Relevance in Lung Adenocarcinoma

Identification of prognostic RNA editing profiles for clear cell renal carcinoma

A-to-I Editing Is Subtype-Specific in Non-Hodgkin Lymphomas

Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma

RNA editing in cancer impacts mRNA abundance in immune response pathways

Non-coding RNA Methylation Modifications in Hepatocellular Carcinoma: Interactions and Potential Implications

Comprehensive Characterization of the RNA Editomes in Cancer Development and Progression.

The roles of RNA editing in cancer immunity through interacting with interferon

Systematically Characterizing A-to-I RNA Editing Neoantigens in Cancer

RNA Over-Editing of BLCAP Contributes to Hepatocarcinogenesis Identified by Whole-Genome and Transcriptome Sequencing

The A-to-I editing of KPC1 promotes intrahepatic cholangiocarcinoma by attenuating proteasomal processing of NF-κB1 p105 to p50